Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Aptevo Therapeutics Inc logo — Our innovative ADAPTIR™ platform technology brings a unique...

Aptevo Therapeutics Inc

Our innovative ADAPTIR™ platform technology brings a unique approach to cancer immunotherapy and improves outcomes.

Founded 2016 United States Seattle, United States 56 employees Post Ipo Equity Total: $56.95M Biopharma, Biotechnology

General Information

Company Name Aptevo Therapeutics Inc
Founded Year 2016
Location United States Seattle, United States +1
Founders / Decision Makers
Team member
Employees 56
Industries Biopharma, Biotechnology
Funding Stage Post Ipo Equity
Social

Get notified when Aptevo Therapeutics Inc moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc is a biotech company with a focus on bringing novel oncology and hematology therapeutics to market. The company prides itself on its innovative ADAPTIR™ platform technology, which offers a unique approach to cancer immunotherapy and aims to improve outcomes for cancer patients. Based in Seattle, Washington, Aptevo boasts an entrepreneurial culture and proprietary platform technology, attracting top talent with experience from pioneering biotech companies such as Trubion, ZymoGenetics, Immunex, Dendreon, and VLST. With a foundation built on ownership and collaboration, Aptevo Therapeutics is charting a course to advance the next frontier in biotechnology. In 2016, the company received a $5.00M post-IPO equity investment on 01 August 2023. As the company continues to make strides in the Biopharma and Biotechnology industries, its focus on innovation, dedication, and development is positioning Aptevo Therapeutics at the forefront of biotechnology advancement.

Taxonomy: Biotech, Cancer Immunotherapy, Oncology, Hematology, ADAPTIR™ Platform Technology, Seattle, Innovation, Entrepreneurial Culture, Science Innovation, Therapeutics, Cancer Research, Empowering Work Environment

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 28 Jun 2024
Post-IPO Equity •••••• - 11 Apr 2024
Post-IPO Equity •••••• - 01 Aug 2023
Post-IPO Debt •••••• - 30 Mar 2023
Post-IPO Debt •••••• - 01 Aug 2016

Aptevo Therapeutics Inc Alternatives & Competitors

Aptevo Therapeutics Inc vs
Sapphire Biotech
Sapphire Biotech

Pioneering advanced therapeutics and diagnostics to enhance global cancer care and ensure early dete...

11-50 employees
Biotechnology, Health Care
Aptevo Therapeutics Inc vs
Halda Therapeutics
Halda Therapeutics United States

Taking Hold, Conquering Cancer. Discovering novel medicines to target cancer and overcome drug resi...

Acquired
39 employees
Biotechnology
Compare Aptevo Therapeutics Inc vs Halda Therapeutics
Aptevo Therapeutics Inc vs
Marengo Therapeutics
Marengo Therapeutics United States

A new frontier in the fight against cancer– the right activation of the right immune cells

Series B
41 employees
Health Care
Compare Aptevo Therapeutics Inc vs Marengo Therapeutics
Also compare with: Aptevo Therapeutics Inc vs Aptadel Therapeutics Aptadel Therapeutics

FAQ About Aptevo Therapeutics Inc

Our innovative ADAPTIR™ platform technology brings a unique approach to cancer immunotherapy and improves outcomes.
Aptevo Therapeutics Inc was founded in 2016.
Aptevo Therapeutics Inc is headquartered in Seattle, United States.
Aptevo Therapeutics Inc operates in the following industries: Biopharma, Biotechnology.
Aptevo Therapeutics Inc has approximately 56 employees.
Aptevo Therapeutics Inc has completed 5 funding rounds, raising a total of $56.95M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Aptevo Therapeutics Inc include Sapphire Biotech, Halda Therapeutics, Marengo Therapeutics, Aptadel Therapeutics, Pi Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aptevo Therapeutics Inc and Sapphire Biotech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Aptevo Therapeutics Inc and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy